ESLA
Price
$0.73
Change
+$0.18 (+32.73%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
23.92M
41 days until earnings call
Intraday BUY SELL Signals
FATE
Price
$2.09
Change
+$0.02 (+0.97%)
Updated
Oct 22 closing price
Capitalization
250.42M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ESLA vs FATE

ESLA vs FATE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ESLA vs. FATE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESLA is a StrongBuy and FATE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ESLA with price predictions
Oct 21, 2026

ESLA's RSI Indicator ascending out of oversold territory

The RSI Indicator for ESLA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 21 of the 24 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 71 cases where ESLA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ESLA as a result. In 62 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.

The Moving Average Convergence Divergence (MACD) for ESLA just turned positive on October 15, 2026. Looking at past instances where ESLA's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.

Following a +44.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ESLA advanced for three days, in 121 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ESLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ESLA entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.219) is normal, around the industry mean (2.988). P/E Ratio (-2.200) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ESLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for FATE with price predictions
Oct 21, 2026

Momentum Indicator for FATE turns negative, indicating new downward trend

FATE saw its Momentum Indicator move below the 0 level on September 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 87 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 47 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

FATE moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for FATE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FATE's RSI Indicator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 64 cases where FATE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

Following a +11.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in 215 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.632) is normal, around the industry mean (2.988). P/E Ratio (-1.990) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
87
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
18
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ESLAFATE
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ESLA: $0.55 vs. FATE: $2.07)
Brand notoriety: ESLA and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ESLA: 441% vs. FATE: 79%
Market capitalization -- ESLA: $31.61M vs. FATE: $250.42M
ESLA [@Biotechnology] is valued at $31.61M. FATE’s [@Biotechnology] market capitalization is $250.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESLA’s FA Score shows that 2 FA rating(s) are green while FATE’s FA Score has 1 green FA rating(s).

  • ESLA’s FA Score: 2 green, 3 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ESLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESLA’s TA Score shows that 6 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • ESLA’s TA Score: 6 bullish, 2 bearish.
  • FATE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ESLA is a better buy in the short-term than FATE.

Price Growth

ESLA (@Biotechnology) experienced а +73.01% price change this week, while FATE (@Biotechnology) price change was +6.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ESLA is expected to report earnings on Dec 02, 2026.

FATE is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ESLA
Daily Signal:
Gain/Loss:
FATE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ESLA and

Correlation & Price change

A.I.dvisor tells us that ESLA and PRLD have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and PRLD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
+37.50%
PRLD - ESLA
25%
Poorly correlated
+3.40%
ARMP - ESLA
25%
Poorly correlated
-4.38%
LIMN - ESLA
23%
Poorly correlated
-2.19%
FATE - ESLA
23%
Poorly correlated
+0.49%
CMND - ESLA
23%
Poorly correlated
-3.10%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BESO34.990.79
+2.32%
GSR Crypto Core3 ETF (BESO)
AIRR99.240.79
+0.80%
First Trust RBA American Industrial Renaissance ETF (AIRR)
NUDV33.550.07
+0.21%
Nuveen ESG Dividend ETF (NUDV)
EHI5.33N/A
N/A
Western Asset Global High Income Fund
LONZ48.72N/A
N/A
PIMCO Senior Loan Active Exchange-Traded Fund (LONZ)